4Q Revenues: $231.9 million (+18.5%)
4Q Earnings: $15 million (+20%)
FY Revenues: $913.3 million (+30%)
FY Earnings: $67 million (+45%)
Comments: The pharmaceutical systems business sales were $164 million, up 20% in the quarter. Significant product area sales gains came from prefilled syringe components, vial stopper products, and disposable syringe components and Flip-Off seals. The Tech Group sales were $70 million in the quarter, up 14%. Revenue growth was driven by $8.9 million in sales of the Exubera Inhalable Insulin device in support of Pfizer's introduction of the product in the U.S., up from $1.1 million in 2Q2005.